[1] V. P. Martinez et al., “Particular person-to-person transmission of Andes virus,” Rising Infectious Illnesses, vol. 11, no. 12, pp. 1848–1853, Dec. 2005. doi: 10.3201/eid1112.050501.
[2] J. D. Pinotti, N. Ortiz, and V. Andreo, Elaboracion de mapas de riesgo por hantavirus para escenarios futuros de cambio climatico en Argentina, Programa EUROCLIMA, 2024. Accessible: https://simarcc.ambiente.gob.ar/
[3] C. B. Jonsson, L. T. Figueiredo, and O. Vapalahti, “A world perspective on hantavirus ecology, epidemiology, and illness,” Medical Microbiology Opinions, vol. 23, no. 2, pp. 412–441, Apr. 2010. doi: 10.1128/CMR.00062-09.
[4] S. Mir, “Hantavirus induced kidney illness,” Frontiers in Drugs, vol. 8, p. 795340, Jan. 2022. doi: 10.3389/fmed.2021.795340.
[5] Facilities for Illness Management and Prevention, “About Hantavirus,” Up to date Might 2024. Accessible: https://www.cdc.gov/hantavirus/about/index.html
[6] Facilities for Illness Management and Prevention, “Clinician Transient: Hemorrhagic Fever with Renal Syndrome.” Accessible: https://www.cdc.gov/hantavirus/hcp/clinical-overview/hfrs.html
[7] W. Lu, L. Kuang, Y. Hu, et al., “Epidemiological and scientific traits of loss of life from hemorrhagic fever with renal syndrome: a meta-analysis,” Frontiers in Microbiology, vol. 15, p. 1329683, Apr. 2024. doi: 10.3389/fmicb.2024.1329683.
[8] World Well being Group, “Illness Outbreak Information: Hantavirus cluster linked to cruise ship journey, Replace,” DON601, Might 13, 2026. Accessible: https://www.who.int/emergencies/disease-outbreak-news/merchandise/2026-DON601
[9] Facilities for Illness Management and Prevention, “About Andes Virus,” Up to date Might 9, 2026. Accessible: https://www.cdc.gov/hantavirus/about/andesvirus.html
[10] T. Avsic-Zupanc, A. Saksida, and M. Korva, “Hantavirus infections,” Medical Microbiology and An infection, vol. 25, Suppl. 1, pp. S45–S51, 2019. doi: 10.1016/j.cmi.2017.05.008.
[11] Z. Bi, P. B. Formenty, and C. E. Roth, “Hantavirus an infection: a evaluate and world replace,” Journal of An infection in Growing International locations, vol. 2, no. 1, pp. 3–23, 2008.
[12] L. Fang, L. Wang, S. J. de Vlas, et al., “Distribution dynamics and urbanization-related components of Hantaan and Seoul virus infections in China between 2001 and 2020,” Infectious Illnesses of Poverty, 2024. PMC11566693.
[13] R. Liu, D. Huang, J. Bai, et al., “Epidemic traits of hemorrhagic fever with renal syndrome in China, 2006–2012,” BMC Infectious Illnesses, vol. 15, p. 156, 2015. doi: 10.1186/s12879-015-0887-1.
[14] R. Yanagihara, H. L. Amyx, and D. M. Asher, “Experimental an infection of immunocompetent and immunodeficient mice and monkeys with Seoul-type hantavirus,” Journal of Virology, vol. 59, no. 1, pp. 70–75, 1986.
[15] E. A. Tkachenko, S. S. Kurashova, A. S. Balkina, et al., “Circumstances of hemorrhagic fever with renal syndrome in Russia throughout 2000–2022,” Viruses, vol. 15, no. 7, p. 1537, Jul. 2023. doi: 10.3390/v15071537.
[16] O. Laine, T. Maki-Marttunen, H. Poyry, et al., “Severity biomarkers in Puumala hantavirus an infection,” Viruses, vol. 14, no. 1, p. 45, Jan. 2022. doi: 10.3390/v14010045.
[17] O. Vapalahti, J. Mustonen, A. Lundkvist, et al., “Hantavirus analysis in Finland: highlights and views,” Viruses, vol. 13, no. 8, p. 1452, 2021. PMC8402838.
[18] Facilities for Illness Management and Prevention, “Reported circumstances of hantavirus illness,” Up to date Apr. 23, 2026. Accessible: https://www.cdc.gov/hantavirus/data-research/circumstances/index.html
[19] W. Merrill, S. Froelich, R. Sherburne, et al., “Profitable therapy of adults with extreme hantavirus pulmonary syndrome with extracorporeal membrane oxygenation,” Crucial Care Drugs, vol. 25, no. 3, pp. 409–414, Mar. 1997.
[20] Facilities for Illness Management and Prevention, “HAN Well being Advisory: 2026 Multi-country Hantavirus Cluster Linked to Cruise Ship,” Might 8, 2026. Accessible: https://www.cdc.gov/han/php/notices/han00528.html
[21] J. W. Huggins, C. M. Hsiang, T. M. Cosgriff, et al., “Potential, double-blind, concurrent, placebo-controlled scientific trial of intravenous ribavirin remedy of hemorrhagic fever with renal syndrome,” Journal of Infectious Illnesses, vol. 164, no. 6, pp. 1119–1127, Dec. 1991. doi: 10.1093/infdis/164.6.1119.
[22] G. J. Mertz, L. Miedzinski, D. Goade, et al., “Placebo-controlled, double-blind trial of intravenous ribavirin for the therapy of hantavirus cardiopulmonary syndrome in North America,” Medical Infectious Illnesses, vol. 39, no. 9, pp. 1307–1313, Nov. 2004. doi: 10.1086/425007.
[23] M. Basu, “There isn’t any vaccine for lethal hantavirus: what meaning for future outbreaks,” Nature, vol. 653, p. 342, Might 2026. doi: 10.1038/d41586-026-01494-9.
[24] V. Vergote, L. Laenen, B. Vanmechelen, et al., “Local weather change and hantavirus,” PLOS Uncared for Tropical Illnesses, vol. 18, no. 9, p. e0012478, Sep. 2024. doi: 10.1371/journal.pntd.0012478.
[25] E. Maciel, J. de Lima Filho, and M. Siqueira, “Local weather change and sugarcane enlargement improve hantavirus an infection danger,” PLOS Uncared for Tropical Illnesses, vol. 11, no. 7, p. e0005705, Jul. 2017. doi: 10.1371/journal.pntd.0005705.
[26] B. Knust, A. Medhanie, T. Viele, et al., “Notes from the sector: Contact tracing investigation after first case of Andes virus in the USA: Delaware, February 2018,” MMWR, vol. 67, no. 39, pp. 1103–1104, Oct. 2018. doi: 10.15585/mmwr.mm6739a4.
[27] Y. Z. Zhang, X. Dong, X. Li, et al., “Hantavirus infections in people and animals, China,” Rising Infectious Illnesses, vol. 16, no. 8, pp. 1195–1203, Aug. 2010. doi: 10.3201/eid1608.090470.
[28] H. W. Lee, P. W. Lee, and Ok. M. Johnson, “Isolation of the etiologic agent of Korean hemorrhagic fever,” Journal of Infectious Illnesses, vol. 137, no. 3, pp. 298–308, Mar. 1978. doi: 10.1093/infdis/137.3.298.
[29] A. T. Jacob, B. M. Ziegler, S. M. Farha, et al., “Sin Nombre virus and the emergence of different hantaviruses,” Biology (Basel), vol. 12, no. 11, p. 1413, Nov. 2023. doi: 10.3390/biology12111413.
[29a] China CDC, “Hemorrhagic fever with renal syndrome and variety and distribution of hantaviruses: China, 2014–2023,” China CDC Weekly, vol. 7, no. 25, 2025. doi: 10.46234/ccdcw2025.141.
[30] J. H. Anstey, N. J. Van Houten, H. S. Morgan, et al., “Hantavirus infections amongst in a single day guests to Yosemite Nationwide Park, California, USA, 2012,” Rising Infectious Illnesses, vol. 20, no. 3, pp. 386–393, Mar. 2014. doi: 10.3201/eid2003.130579.
[31] R. A. Jonsson, M. G. Melo, S. A. Roediger, et al., “‘Tremendous-spreaders’ and person-to-person transmission of Andes virus in Argentina,” New England Journal of Drugs, vol. 383, no. 23, pp. 2230–2241, Dec. 2020. doi: 10.1056/NEJMoa2009040.
[32] J. Hepojoki, A. Vaheri, and T. Strandin, “The elemental function of endothelial cells in hantavirus pathogenesis,” Frontiers in Microbiology, vol. 5, p. 727, Dec. 2014. doi: 10.3389/fmicb.2014.00727.
[33] H. Guo, Y. Hu, Q. Zhang, and F. Li, “Vaccines and therapeutics towards hantaviruses,” Frontiers in Microbiology, vol. 10, p. 2989, Dec. 2019. doi: 10.3389/fmicb.2019.02989.
